iOnctura operates as a clinical-stage biotechnology company that specializes in developing a treatment for cancer.
iOnctura has raised €113M across 4 funding rounds from 10 investors, most recently a Series B round in Jun 2024. Based in Geneva, Switzerland; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-06-24 | Series B | €80M | 3B Future Health Fund,EIC Fund,Inkef Capital,M Ventures,Schroders Capital,Syncona Limited+1 more | View deal → |
| 2022-12-21 | Other | €18M | EIC Accelerator | View deal → |
| 2022-09-22 | Seed | €413k | Fongit Innovation Fund (FIF) | View deal → |
| 2020-01-23 | Series A | €15M | INKEF Capital,VI Partners | View deal → |
